Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood test may forecast heart valve risks

NCT ID NCT04571372

Knowledge-focused Sponsor: Yonsei University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time

Summary

This study looks at whether a substance in the blood called suPAR can help predict serious health events in people with severe aortic stenosis or regurgitation. Researchers will measure suPAR levels and track participants for two years to see if higher levels are linked to death, heart-related death, or worsening kidney function. The goal is to find a simple blood test that could flag those at higher risk.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If suPAR levels are linked to worse outcomes, this could help doctors identify high-risk patients earlier.
What could go wrong
This is an observational study, not a treatment trial. It may find no strong link, and results may not change care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

222 people

The number who actually took part.

Started

Aug 2020

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with severe aortic stenosis or severe aortic regurgitation

Ages

19 to 99 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 19 yrs * Severe aortic stenosis or severe aortic regurgitation * Agree to consent for self * Can follow-up for the next 2 years Exclusion Criteria: * Pre-existing acute kidney injury * Pre-existing end stage kidney disease: estimated glomerular filtration rate (eGFR) ≤15 ml/min/1.73m2 or receiving renal replacement therapy * On ECMO or IABP * Life expectancy \< 12 months * Pregnancy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Severe aortic stenosis or severe aortic regurgitation are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

aortic valve insufficiency aortic valve stenosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Severe aortic stenosis or severe aortic regurgitation

Contacts and locations

Locations

  • Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine

    Seoul, South Korea